To further clarify the mechanism by which sEH/COX-2 metabolism disorders accelerate NAFLD, we observed sEH/COX-2 metabolism in vitro, which was consistent with the tissue level of our previous study, showing significantly increased protein expressions of sEH and COX-2. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatotic liver disease.